HBV infection in patients with end-stage renal disease

Fabrizio Fabrizi, Suphamai Bunnapradist, Paul Martin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Controlling the spread of hepatitis B virus (HBV) infection in dialysis units has been one of major triumphs in the management of end-stage renal disease. However, HBV incidence and prevalence rates remain high in dialysis patients in less-developed countries, and HBV within dialysis units continues to spread in the industrialized world. Overall response rates to HBV vaccination are lower in dialysis patients than in the nondialysis population. Lamivudine is effective in the treatment of HBV infection in the dialysis setting. Presence of hepatitis B surface antigen (HbsAg) has a negative impact on patient survival after renal transplantation. Several issues remain unanswered with regard to the management of HBV infection in dialysis patients, including the management of lamivudine resistance and the optimal timing and duration of antiviral therapy. Liver biopsy prior to renal transplantation is crucial in order to identify and exclude patients with advanced fibrosis or even cirrhosis.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalSeminars in Liver Disease
Volume24
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 18 2004
Externally publishedYes

Fingerprint

Virus Diseases
Hepatitis B virus
Chronic Kidney Failure
Dialysis
Lamivudine
Kidney Transplantation
Fibrosis
Hepatitis B Surface Antigens
Developing Countries
Antiviral Agents
Vaccination
Biopsy
Survival
Liver
Incidence
Therapeutics
Population

Keywords

  • Hepatitis B virus
  • Lamivudine
  • Renal disease
  • Therapy

ASJC Scopus subject areas

  • Hepatology

Cite this

HBV infection in patients with end-stage renal disease. / Fabrizi, Fabrizio; Bunnapradist, Suphamai; Martin, Paul.

In: Seminars in Liver Disease, Vol. 24, No. SUPPL. 1, 18.06.2004, p. 63-70.

Research output: Contribution to journalArticle

Fabrizi, Fabrizio ; Bunnapradist, Suphamai ; Martin, Paul. / HBV infection in patients with end-stage renal disease. In: Seminars in Liver Disease. 2004 ; Vol. 24, No. SUPPL. 1. pp. 63-70.
@article{4999e1d8189643bcb234be02fd54b080,
title = "HBV infection in patients with end-stage renal disease",
abstract = "Controlling the spread of hepatitis B virus (HBV) infection in dialysis units has been one of major triumphs in the management of end-stage renal disease. However, HBV incidence and prevalence rates remain high in dialysis patients in less-developed countries, and HBV within dialysis units continues to spread in the industrialized world. Overall response rates to HBV vaccination are lower in dialysis patients than in the nondialysis population. Lamivudine is effective in the treatment of HBV infection in the dialysis setting. Presence of hepatitis B surface antigen (HbsAg) has a negative impact on patient survival after renal transplantation. Several issues remain unanswered with regard to the management of HBV infection in dialysis patients, including the management of lamivudine resistance and the optimal timing and duration of antiviral therapy. Liver biopsy prior to renal transplantation is crucial in order to identify and exclude patients with advanced fibrosis or even cirrhosis.",
keywords = "Hepatitis B virus, Lamivudine, Renal disease, Therapy",
author = "Fabrizio Fabrizi and Suphamai Bunnapradist and Paul Martin",
year = "2004",
month = "6",
day = "18",
doi = "10.1055/s-2004-828680",
language = "English",
volume = "24",
pages = "63--70",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "SUPPL. 1",

}

TY - JOUR

T1 - HBV infection in patients with end-stage renal disease

AU - Fabrizi, Fabrizio

AU - Bunnapradist, Suphamai

AU - Martin, Paul

PY - 2004/6/18

Y1 - 2004/6/18

N2 - Controlling the spread of hepatitis B virus (HBV) infection in dialysis units has been one of major triumphs in the management of end-stage renal disease. However, HBV incidence and prevalence rates remain high in dialysis patients in less-developed countries, and HBV within dialysis units continues to spread in the industrialized world. Overall response rates to HBV vaccination are lower in dialysis patients than in the nondialysis population. Lamivudine is effective in the treatment of HBV infection in the dialysis setting. Presence of hepatitis B surface antigen (HbsAg) has a negative impact on patient survival after renal transplantation. Several issues remain unanswered with regard to the management of HBV infection in dialysis patients, including the management of lamivudine resistance and the optimal timing and duration of antiviral therapy. Liver biopsy prior to renal transplantation is crucial in order to identify and exclude patients with advanced fibrosis or even cirrhosis.

AB - Controlling the spread of hepatitis B virus (HBV) infection in dialysis units has been one of major triumphs in the management of end-stage renal disease. However, HBV incidence and prevalence rates remain high in dialysis patients in less-developed countries, and HBV within dialysis units continues to spread in the industrialized world. Overall response rates to HBV vaccination are lower in dialysis patients than in the nondialysis population. Lamivudine is effective in the treatment of HBV infection in the dialysis setting. Presence of hepatitis B surface antigen (HbsAg) has a negative impact on patient survival after renal transplantation. Several issues remain unanswered with regard to the management of HBV infection in dialysis patients, including the management of lamivudine resistance and the optimal timing and duration of antiviral therapy. Liver biopsy prior to renal transplantation is crucial in order to identify and exclude patients with advanced fibrosis or even cirrhosis.

KW - Hepatitis B virus

KW - Lamivudine

KW - Renal disease

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=2942590734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942590734&partnerID=8YFLogxK

U2 - 10.1055/s-2004-828680

DO - 10.1055/s-2004-828680

M3 - Article

VL - 24

SP - 63

EP - 70

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - SUPPL. 1

ER -